Isoxicam
Chemical compound
![]() |
|
Clinical data | |
---|---|
Trade names | Maxicam |
ATC code | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
CompTox Dashboard ( EPA ) | |
ECHA InfoCard |
100.047.334
![]() |
Chemical and physical data | |
Formula | C 14 H 13 N 3 O 5 S |
Molar mass | 335.33 g·mol −1 |
3D model ( JSmol ) | |
|
Isoxicam is a nonsteroidal anti-inflammatory drug (NSAID) that was taken or applied to reduce inflammation and as an analgesic reducing pain in certain conditions. The drug was introduced in 1983 by the Warner-Lambert Company . Isoxicam is a chemical analog of piroxicam (Feldene) which has a pyridine ring in lieu of an isoxazole ring. In 1985 Isoxicam was withdrawn from the French market, due to adverse effects, namely Toxic Epidermal Necrolysis ( Lyell syndrome ) resulting in death. Although these serious side effects were observed only in France, the drug was withdrawn worldwide. [1] [2]
References
- ↑ Consolidated List of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by Governments , United Nations, 2003, p. 123 link to 2005 ed
- ↑ Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science . 35 (1): 293–317. doi : 10.1177/009286150103500134 . S2CID 73036562 .
pyrazolones
/
pyrazolidines |
|
---|---|
salicylates | |
acetic acid
derivatives
and related substances |
|
oxicams | |
propionic acid
derivatives (profens) |
|
n
-arylanthranilic
acids ( fenamates ) |
|
COX-2 inhibitors
(coxibs) |
|
other | |
NSAID
combinations |
|
Key:
underline
indicates initially developed first-in-class compound of specific group;
#
WHO-Essential Medicines
;
†
withdrawn drugs
;
‡
veterinary use
.
|
|